Viral Hepatitis Prevention and Control

 

Program activities support integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C. Partners should develop a jurisdictional viral hepatitis elimination plan, increase comprehensive hepatitis B and C reporting, improve HBV and HCV testing and increase healthcare providers trained to treat hepatitis B and C. Contingent on funding, the following activities can be supported: surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings (syringe services programs (SSPs), substance use disorder (SUD) treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics; and increased access to services preventing viral hepatitis and other infections among persons who inject drugs (PWID). Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of viral, bacterial and fungal infections related to drug use in settings disproportionately affected by drug use. Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.

Active 93.270 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants Not applicable. Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments Sections 301 and 317K(k)(2) of the Public Health Service Act (42 U.S.C. section 241 and 274b-15), as amended Applicants include State or local governments or their Bona Fide Agents, public and private nonprofit organizations, for profit organizations, small, minority, women-owned businesses, universities, colleges, research institutions, hospitals, community-based organizations, faith based organizations, Federally recognized Indian tribal governments, Indian tribes, and Indian tribal organizations. Additional guidance may be provided in individual program announcements. In addition, funds may be used for costs associated with establishing and maintaining a prevention and control program directed towards prevention of viral hepatitis infections and their manifestations. Recipients may only expend funds for reasonable policies, systems and program purposes including personnel, travel, supplies and services, such as reducing transmission of HAV, HBV and HCV, preventing and delaying the progress of chronic infection, as well as educating and training of the general public and health care providers. Recipients may not use funds for clinical care. Recipients may not generally use funding for the purchase of furniture or equipment. Any such proposed spending must be identified in the budget. The recipient must perform a substantial role in carrying out project objectives and not merely serve as a conduit for an award in another party or provider who is eligible. The general public will benefit from the objectives of this program as well society from the savings realized from treating those that are infected with viral hepatitis. Not applicable. Preapplication coordination is not applicable. This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any. Contact the headquarters or regional location, as appropriate for application deadlines From 120 to 180 days. Not applicable. From 120 to 180 days. Cooperative agreement period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government. Applications will be evaluated on the review criteria described in the Notice of Funding Opportunity Announcements (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC. Funds may be used for costs associated with establishing and maintaining a prevention and control program directed towards prevention of viral hepatitis infections and their manifestations. Recipients may only expend funds for reasonable policies, systems and program purposes including personnel, travel, supplies and services, such as reducing transmission of HAV, HBV and HCV, preventing and delaying the progress of chronic infection, as well as educating and training of the general public and health care providers. Performance Reports: Annual Federal Financial Reports (FFR) and performance/progress reports are required. Final FFRs and performance reports are required. Other reporting may be required and will be outlined in the NOFO or the Notice of Award. Not applicable. In accordance with 2 CFR ?200, as codified in 45 CFR ?75, there is a 3-year record retention requirement; records shall be retained beyond the 3-year period if final audit has not been done or findings resolved. Property records must be retained in accordance with HHS Grants Policy Statement requirements. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient. Notice of Award None/Not specified. Megan B. Copeland
1600 Clifton Road, MS E-07
Atlanta, GA 30329 US
mzf3@cdc.gov
Phone: 4046398864

Nicolas Rankin
1600 Clifton Road, MS E-07
Atlanta, GA 30329 USA
xkx6@cdc.gov
Phone: 4044980226 http://www.cdc.gov/ 09-2950-2-0-131 (Cooperative Agreements) FY 22$24,234,898.00; FY 23 est $26,911,643.00; FY 24 est $26,911,643.00; FY 21$23,072,990.00; FY 20$16,241,093.00; - Awards will range from approximately $275,000 to $617,000, with an average award of $386,000. Not applicable. Not applicable.